APL-5125 / Apollo Therap - LARVOL DELTA

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=100 | Active, not recruiting | Sponsor: Apollo Therapeutics Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Appendix Cancer • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Endometrial Adenocarcinoma • Endometrial Cancer • Gastric Adenocarcinoma • Gastric Cancer • Genito-urinary Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer • KRAS

Selective Inhibition of CK2: Emerging Strategies and Future Directions. (PubMed, J Med Chem) - "Validation of the αD pocket as a ligandable cryptosteric site enabled dual-site ligands such as CAM4066 and αD-directed inhibitors such as CAM4712, followed by related advances including AB668, KDX1381 and Biv5. These efforts culminated in APL-5125, a highly selective, subnanomolar dual-site inhibitor now in Phase 1/2 clinical evaluation."

Journal • Review • CNS Disorders • Infectious Disease • Oncology

Exploiting the Cryptic αD Pocket of Casein Kinase 2α (CK2α) to Deliver Highly Potent and Selective Type 1 Inhibitors. (PubMed, J Med Chem) - "A drug discovery project to develop a new series of bivalent CK2α inhibitors with increased cell potency and selectivity identified 61f (APL-5125), a highly potent, ATP-competitive CK2α inhibitor with exquisite kinase selectivity and cellular potency. Compound 61f demonstrates in vivo inhibition of p-AKT S129 in tumors (HCT116) following once-daily oral administration and shows a clear PK-PD relationship with unbound drug exposure. 61f has a superior preclinical profile to existing CK2α inhibitors and is currently under evaluation in patients with advanced solid tumors."

Journal • Oncology • Solid Tumor

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Apollo Therapeutics Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Appendix Cancer • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Endometrial Adenocarcinoma • Endometrial Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=100 | Not yet recruiting | Sponsor: Apollo Therapeutics Ltd

Metastases • New P1/2 trial • Appendix Cancer • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Endometrial Adenocarcinoma • Endometrial Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer